Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
AstraZeneca
Colorcon
Citi
Daiichi Sankyo
Dow
Argus Health
Johnson and Johnson
Harvard Business School

Generated: May 23, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021896

« Back to Dashboard

NDA 021896 describes EMTRIVA, which is a drug marketed by Gilead and is included in two NDAs. It is available from four suppliers. There are three patents protecting this drug and one Paragraph IV challenge. Additional details are available on the EMTRIVA profile page.

The generic ingredient in EMTRIVA is emtricitabine. There are seventeen drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the emtricitabine profile page.
Summary for 021896
Tradename:EMTRIVA
Applicant:Gilead
Ingredient:emtricitabine
Patents:3
Therapeutic Class:Antivirals
Formulation / Manufacturing:see details
Pharmacology for NDA: 021896
Medical Subject Heading (MeSH) Categories for 021896
Suppliers and Packaging for NDA: 021896
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
EMTRIVA emtricitabine SOLUTION;ORAL 021896 NDA Gilead Sciences, Inc. 61958-0602 N 61958-0602-1

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;ORALStrength10MG/ML
Approval Date:Sep 28, 2005TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Jan 2, 2018Product Flag?Substance Flag?Delist Request?
Patent:➤ Try a Free TrialPatent Expiration:May 4, 2021Product Flag?Substance Flag?Delist Request?Y
Patent:➤ Try a Free TrialPatent Expiration:Sep 9, 2021Product Flag?Substance Flag?Delist Request?Y

Expired US Patents for NDA 021896

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Gilead EMTRIVA emtricitabine SOLUTION;ORAL 021896-001 Sep 28, 2005 ➤ Try a Free Trial ➤ Try a Free Trial
Gilead EMTRIVA emtricitabine SOLUTION;ORAL 021896-001 Sep 28, 2005 ➤ Try a Free Trial ➤ Try a Free Trial
Gilead EMTRIVA emtricitabine SOLUTION;ORAL 021896-001 Sep 28, 2005 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Argus Health
Cerilliant
Baxter
Teva
UBS
Boehringer Ingelheim
US Department of Justice
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.